MicroRNAs and other non-coding RNAs as targets for anticancer drug development
By H. Ling, M. Fabbri, George A. Calin. Nature reviews. Drug discovery, 2013
1,416 citations recorded by the source corpus.
The first cancer-targeted microRNA (miRNA) drug — MRX34, a liposome-based miR-34 mimic — entered Phase I clinical trials in patients with advanced hepatocellular carcinoma in April 2013, and miRNA therapeutics are attracting special attention from both academia and biotechnology companies. Although miRNAs are the most studied non-coding RNAs (ncRNAs) to date, the importance of long non-coding RNAs (lncRNAs) is increasingly being recognized. Here, we summarize the roles of miRNAs and lncRNAs in cancer, with a focus on the recently identified novel mechanisms of action, and discuss the current strategies in designing ncRNA-targeting therapeutics, as well as the associated challenges.
Subfields: Cancer Research, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/e9b1e72873bbdd773bf9efbe06b7469889e3ecbd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Molecular Biology
Citations in the corpus
- The delivery of therapeutic oligonucleotides (2016, background): “While attempts to therapeutically exploit ncRNAs are just beginning, there is a great deal of interest in the potential of this approach (29).”